Pathways to the discovery of the Aβ amyloid of Alzheimer's disease

Article type: Research Article

Authors: Masters, Colin L.^{a; *} | Beyreuther, Konrad^b

Affiliations: [a] Department of Pathology, The University of Melbourne, and the Mental Health Research Institute of Victoria, Australia | [b] Centre for Molecular Biology, The University of Heidelberg, Germany

Correspondence: [*] Corresponding author: Colin L. Masters, Department of Pathology, The University of Melbourne, Victoria 3010, Australia. Tel.: +61 3 8344 5868; E-mail: c.masters@unimelb.edu.au.

Abstract: Many participants played a role in discovering the composition and sequence of the Aβ amyloid of Alzheimer's disease. This sequence enabled the cloning of the amyloid precursor protein (APP), which elucidated its proteolytic origin from the membrane of neurons. The proteolytic enzymes which process APP and the Aβ fragment itself are now the prime validated drug targets for therapeutic intervention.

DOI: 10.3233/JAD-2006-9S318

Journal: Journal of Alzheimer's Disease, vol. 9, no. s3, pp. 155-161, 2006